Long Acting Injectables Explained - Info Session with Indivior + Camurus

Dear colleagues

As you are aware there are two new long-acting-injectable buprenorphine (LAI-B) products available in Australia:

1) Sublocade, by Indivior

2) Buvidal, by Camurus

Due to high level of interest in these new products, Insight is coordinating a free seminar/webinar featuring representatives from both Camurus and Indivior who will be providing an overview of their respective products.

Each session will cover:

• Technology behind the LAIs

• Pharmacokinetics
  

• Dosage / strengths / injection volumes

• Storage requirements

• Blockade of LAI

• Conversion of patients from Methadone / Suboxone to LAI

• Dosing windows

• Demonstration of administration / video

• Costs / benefits for patients

This event can be attended in person or as an online webinar. Registration is required for both options - please select the ticket type applicable to you during the registration. 

Webinar participants will be emailed a special link to the webinar in the days preceding the event.

NB: Registration is limited to Qld-based AOD health workers only, and priority will be given to staff employed within OST clinics.

Please note, this webinar will not be film-recorded, and is not catered (tea and coffee available only).

We hope you can join us!

Kind regards

Insight: Centre for AOD Training and Workforce Development